Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com
Second quarter GAAP revenue of $904 million and non-GAAP revenue of $906 million
Second quarter GAAP earnings per share of $0.58 and non-GAAP earnings per share of $0.91
Free cash flow of $203 million in the second quarter
CARLSBAD, Calif., Jul 29, 2010 (BUSINESS WIRE) -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for its second quarter ending June 30, 2010. Non-GAAP revenue for the second quarter was $906 million, an increase of 8 percent over the $839 million r...
AUSTIN, Texas & CARLSBAD, Calif., Jul 13, 2010 (BUSINESS WIRE) --Asuragen,
Inc. and Life
Technologies Corporation (NASDAQ: LIFE) announced today that they
have achieved CE-marking and commercial launch in Europe of the BCR/ABL1
Quant(TM) Test, Asuragen's clinically validated and cGMP manufactured test
intended to aid clinicians in the monitoring and treatment of
individuals afflicted with chronic myeloid leukemia (CML). Asuragen
manufac...
CARLSBAD, Calif., Jul 08, 2010 (BUSINESS WIRE) --Life Technologies Corporation (NASDAQ:LIFE) today announced an
unprecedented program that streamlines the detection of three common
contaminants of mammalian cell culture-based biopharmaceutical
manufacturing. The Applied
Biosystems Cell Culture Rapid Methods Program applies core
technologies from across the company to combine one sample preparation
step with one instrument platform for real-time PCR...
CARLSBAD, Calif., Jul 07, 2010 (BUSINESS WIRE) -- Life Technologies Corporation (NASDAQ: LIFE) announced today that it has given notice of its intention to redeem all of the outstanding 2% Convertible Senior Notes due 2023 (the "2023 Convertible Notes") on August 6, 2010. As of June 30, 2010 there was $349,544,000 in aggregate principal amount of the 2023 Convertible Notes outstanding. The redemption notice provided includes cusips 46185RAF7 and 46185RAJ9.
The 2023 Convertible Notes are conve...
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
